On December 27, a powerful magnetic storm will hit the Earth as numerous solar flares have been detected on the Sun. On this day, it is advisable to reduce physical and mental exertion to avoid worsening well-being, according to the news outlet The Watchers.
The strength of the magnetic storm
Solar activity has increased to a moderate level, with researchers detecting flares of class M on the star’s surface.
Additionally, on December 24, a coronal mass ejection began. Initial analysis suggests a potential impact of this phenomenon until late in the night on December 27.
Thus, unstable conditions of the geomagnetic field will be felt until the end of the day on December 27.
Many solar flares have been detected on the Sun. A strong magnetic storm is expected to hit the Earth in the next few hours.
Detected solar flares (photo: watchers.news)
What are solar storms
These are explosive processes on the Sun characterized by the ejection of massive streams of energy, various particles, and electromagnetic radiation into space.
Most of these electrically charged particles head towards Earth. Upon entering the planet’s magnetic field, they interact with it, causing disruptions.
Particles from space can interfere with the operation of satellites, power grids, and communication systems. Solar storms are also responsible for occasional disruptions in GPS, mobile communication, television, etc.
Interestingly, the occurrence of strong solar storms is also the cause of the appearance of the northern and southern polar lights.
How to ease this period
The impact of magnetic storms varies individually. People with particularly heightened sensitivity may experience headaches, migraines, changes in blood pressure, and worsened blood clotting.
To avoid unpleasant consequences, paying attention to proper sleep is advised. Doctors recommend going to bed an hour before midnight and waking up without an alarm clock.
Remember physical activity: walk, swim, engage in gymnastics. However, do not exhaust yourself with strength training in the gym.
If you have a headache, it’s better to avoid drinks containing caffeine, which creates additional stress for the body. Instead, prefer herbal teas.
Be patient Florida, this too, shall pass! Steven M Smith InspirationalTech.org CEO since 2013.
The majority of the psychedelics community has rarely made contact with the world of venture capital and high-growth startups.
This is dangerous because it doesn’t allow for those that work with psychedelic substances to understand what the next 10 years will bring their way… and as of right now the future doesn’t look too bright.
A Venture Capital (VC) firm, is in its simplest form just an entity that invests the money of rich folks into the companies that it believes will become the most financially valuable. There are of course other considerations for some investing groups such as: patient outcomes, environmental impact and sustainability, and general ESG methodologies. But for the most part VC firms work to provide a return, financial gain,to their investors by providing cash to startups that want to grow their business fast.
Let’s say that you are a psychotherapist who’s been running their own clinic for a few years. You were trained by MAPS to do psychedelic assisted therapy and have incorporated the service into your practice. Business is booming. Everyone wants access to your transformative care.
Perhaps you want to open up a second clinic where you can hire on some more therapists with the proper training, but you don’t have the money saved up yet to open up another location.
You could wait a few years, go to a bank to get a loan, or you could seek out an investment.
If you choose to go raise money for your venture you’ll be met with a lot of questions most of which will be pointed at one thing: scale. Most investors won’t put down capital for you to just open up one additional clinic. You’ll need to describe a vision of growing fast and scaling your brand to be the most impactful, widely distributed clinic on the planet.
Why? Because investors lose money on most investments that they make. Almost all of their returns are made from the few investments that knock it out of the park. The billion dollar unicorn that can grow their money more than 100x.
None of this is to say that good companies that can generate a high return don’t exist, but it’s very difficult to find that balance. Within our current system, companies need to compete with one another. That competition plays out through cutting costs, moving quickly, and oftentimes deprioritizing people, the environment, and quality.
It’s also very difficult to prioritize long term results. Every VC firm collects a new pool of money every few years called a fund. Most funds only run for 7 years, 10 years on the long end. Within 10 years you need to see a company sold off or going public for you to cash out and see the fruits of your investment. A company that has a 25 year mission to revolutionize patient care, but has to suffer losses for the first 10? Not going to happen.
As I mentioned earlier, there are strategies for forming firms around values, impact, and longer term results. But it’s extremely difficult. A firm can focus on investing in B Corps, but B Corp status is very time and resource intensive to pursue. There are a few companies in the space that have done it including MAPS and The Third Wave, but it’ll be a long road before we see a meaningful percentage of psychedelics companies adopt this style of doing business.
All of us from Auryn Fund, to Field Trip, to our own Tabula Rasa Ventures are trying hard to make sure that the future of this industry reflects the incredible community that’s built it. But we need to be having more open conversations along with detailed strategies for how to do investment right.
How to Raise Capital for a Psychedelic Startup: Industry Info You Need to Know
In the recent past, psychedelics were considered dangerous drugs. Today, more and more scientists recognize their medical potential. Investors are already investing in the young industry.
Psychedelic drugs have a complicated history. They had a heyday in the 1960s but then fell into disuse. Recent research has partially brought psychedelics back. Today, scientists see them as promising compounds for treating many diseases.
Given the above, it is quite fair to say that the era of the so-called psychedelic renaissance has begun. Since 2020, the number of psychedelic companies has started to increase greatly.
Let’s take a look at the reasons for the increased demand in the psychedelic industry. Learn how to raise capital dealing with this type of business.
Psychedelics Boom
Despite Covid-19 and the collapse of the economy, investors are starting to pay attention to this industry. They bet that psychedelic-derived drugs can become a real business and help millions of people. Researchers, activists, and journalists have been the driving force behind the psychedelic renaissance.
Benefits of Psychedelics
Many startup companies are developing drugs based on psilocybin (the active ingredient in magic mushrooms), LSD, MDMA, and ibogaine. They are banned in the United States, except ketamine, which is also used in the development of such medicine. These companies hope to develop a psychedelic therapy treatment for a wide range of mental illnesses. They include depression, anxiety, addiction, and post-traumatic stress disorder (PTSD).
Medical regulators are also gradually turning toward psychedelics, as they show potential in treating depression. In 2019, the Food and Drug Administration (FDA) called Usona Institute’s psilocybin program for major depressive disorder “breakthrough therapy.”
However, researchers will have a tough road to winning FDA approval.
How Medical Companies Turned to Psychedelics
In early 2020, the drug company Mind Medicine (MMEDF) went public. It received the financial backing of Kevin O’Leary and the guidance of cannabis entrepreneur Bruce Linton. In one interview, O’Leary explained his reasons for investing in psychedelics and talked about the lagging efforts to treat growing psychiatric disorders.
In 2013, Linton became a co-founder of Canopy Growth (CGC), the largest cannabis company in the U.S. He left in 2019 and later became director of Mind Medicine. The main goal of the company is similar to Compass Pathways. They plan to bring psychedelics to market and conduct research on LSD, mushrooms, and other drugs.
Investing in Psychedelics
Venture capital investors were at the centre of the psychedelic boom. In early 2020, startups in the field said they were beginning to see signs of growing investor appetite.
Venture capital firms focused on psychedelic companies soon began to appear. Insider’s list of the top 11 venture capitalists in the field shows $139.8 million invested in such startups in just a few years.
Kevin O’Leary and PayPal co-founder Peter Thiel make big bets on magic mushrooms. Their big plans for mind-altering mushrooms have nothing to do with festivals or raves but deal with biotech instead.
Negev Capital, a psychedelic medical intervention investment fund, invests in companies that are developing new drugs to treat mental disorders based on psychedelic compounds. Negev has invested in 20 psychedelic drug development companies and has more than $30mln under the management
The fund recently doubled down on its substantial investment in Small Pharma Inc, a neuropharmaceutical company specialising in developing new treatments for mental illness with a focus on depression.
Another representative of psychedelic medicine is ATAI Life Sciences. It’s a “drug discovery platform” from Germany. The company invests in research of possible uses of psychedelics and other drugs for medical purposes. As of January 2021, they had raised more than $210 million, much of it from Thiel Capital and Christian Angermayer.
ATAI Life Sciences has taken a majority stake in Recognify, which was founded by Thomas Südhof, winner of the 2013 Nobel Prize in Physiology and Medicine. Recognify’s aim is to develop drugs to help treat schizophrenia. The company focuses on cognitive impairments (CIAS) that interfere with verbal learning and memory. Their new drug, RL-007, although not derived from psychoactive compounds, has already undergone positive clinical trials.
Another company is Compass Pathways (CMPS), which went public in the United States back in September 2020. The British company, invested in by Thiel and Angermayer, has patented a synthetic form of psilocybin. It helps people with treatment-resistant depression.
The company launched clinical trials that involved 233 patients at several sites across Europe and North America. It is the most rigorous trial on psilocybin, which adds great weight to previous, smaller studies of the drug. In November 2018, FDA called the company’s treatment “breakthrough therapy.” This means the approval may come soon if trials are successful. Compass will start Phase 3 trials in the near future.
Cybin is a biotech company focused on the development of psychedelic therapeutics. In October 2021, it completed its 74th pre-clinical study of psychedelic compounds for potential therapeutic applications in several psychiatric disorders. Over 50 new compounds have been evaluated with the help of experienced contract research organizations.
The company seeks to build a portfolio of world-class psychedelic molecules that could become commercially viable drug candidates for both internal development and future partnerships.
The current psychedelic boom is only the beginning of the industry’s development and expansion. Considering investors’ attention to this type of medicine, more startups will emerge in the future. Active research on psychedelics has resumed in recent years, after its peak in the 1950s and 1970s. It may lead to great scientific progress and heal millions of people.
1st Hemp USA News is a resource of Inspirational Technologies (2021-2023)Inspirational Technologies (2023) AllRightsReservedYour ONE STOP BLOG FOR INFORMATION, EDUCATION, & INSPIRATION OF ESSENTIAL INNOVATION & RENOVATION of You-THANK YOU FOR YOUR INTEREST*This site receives virtually no compensation for sales of some or all mentioned products. We however place humanitarian value over monetary interests. Our monetary income goes back into research, development, discovery and healing.Inspirational Technologies – is Committed to Your Health Wellness Beauty and EnrichmentReporting on Today’s Internal Botanical and Skin Product Benefits
4 Hemp Club was Inspired by Steven Smith’s vision to “Have an older generation 4H Club, where an older community of adults could carry on what the younger 4H Club envisioned.
Our 4H Platform Uses HEMP as an Agricultural Focal Point, deserving of research, development and with the
4 Hemp key points being Health Hope and Happiness, thru Hemp“.
Cannabis CBD and Me Inspirational Technologies Inspirational Technologies (2014) @Inspire123tech Background Noise Studios Logos bySteven M Smith
Many startup companies are developing drugs based on psilocybin (the active ingredient in magic mushrooms), LSD, MDMA, and ibogaine. They are banned in the United States, except ketamine, which is also used in the development of such medicine. These companies hope to develop a psychedelic therapy treatment for a wide range of mental illnesses. They include depression, anxiety, addiction, and post-traumatic stress disorder (PTSD).
As the cannabis industry holds its breath while waiting to hear if marijuana banking reform will be part of a must-pass omnibus spending bill, James Hagedorn, a CEO of the lawn care giant Scotts Miracle-Gro (NYSE: SMG) shared
Scotts Miracle-Gro’s 2014 development of subsidiary Hawthorne Gardening Company “to meet the demands of hydroponic (cannabis) was considered one of the first large investments by a major U.S. corporation in the marijuana space. Nevertheless, Hagedorn wants to see the SAFE Banking Act passed for more than merely personal reasons.
It’s Not About Legal Pot
In an exclusive interview with Fox Business, Hagedorn pointed out that the idea behind the banking legislation is not to make pot legal but to allow businesses that represent the legal cannabis market to use banks, instead of having cash everywhere.
“It’s very dangerous. It’s inefficient. It’s really dysfunctional for the banking industry, not to be able to take this money in, allow people to deposit in, make capital investments in illegal businesses,” Hagedorn said.
The interview came on the heels of Senate Minority Leader Mitch McConnell calling the banking bill a “poison pill.”
It looks like the SAFE Act needs the support of both McConnell, and Senate Majority Leader Chuck Schumer, the reporter said and asked Hagedorn what he’d say to them if they were listening.
“Well, first of all, I think there are 60 votes to get this out of the Senate. It’s been passed multiple times on a bipartisan basis in the House with a lot of Republican support, and there are some really good people out there. The co-sponsor on the Republican side in the Senate is a guy named Steve Daines. He’s a really good Republican. I’m a Republican, out of Montana, and what he told me is – ‘Jim, I’m not in favor of marijuana,” Hagedorn said. “What I’m not in favor of is dysfunction and banking. In my state, by voter initiative, they made it legal. And if it’s going to be legal, my citizens should be able to bank.’”
Hagedorn continued. “This is not about pot. This is about dysfunction in banking, people today have to pay taxes on legal businesses with duffel bags of cash and counting machines like Scarface. It’s not the way it’s supposed to be in America. There are almost a half million people that are employed in this space. Americans that vote. They have problems getting mortgages this way. These are all people who are working in legal industries. This is dysfunctional and bad, and all the Senate has to do is allow legal businesses legal access to banking. “
Ifs the bill passes during the lame-duck session, Hagedorn says he doesn’t believe that big financial names like JP Morgan Chase (NYSE: JPM) and Fifth Third (NASDAQ: FITB), are going to embrace the industry in the same instant because there’s “a lot of sensitivity about compliance.”
While many believe the SAFE Act is a small step in much-needed marijuana reform, Hagedorn agreed with Senator Danes that it is indeed a big step forward in rationalizing banking for legal businesses.
“Let’s remember one thing when you have a lot of cash, it brings crime. There are people killed every day, where they have a lot of cash lying around. And people have to take this money in cash.”
Price Action
Scotts Miracle Grow shares were trading 0.39% higher at $48.50 per share during Monday’s pre-market session.
UPDATE ON OMNIBUS SPENDING BILL
Marijuana advocates were given a massive setback after the Senate did not include a provision to remove federal restrictions on cannabis businesses from receiving banking services in the $1.7 trillion omnibus spending bill.
The provision, which would have been modeled after the House’s SAFE Banking Act, was excluded from the Senate’s spending bill, likely thanks to Senate Minority Leader Mitch McConnell (R-KY), who has been a fierce opponent of the legislation.
The CEO of the U.S. Cannabis Council, a pro-marijuana group, said of the provision’s exclusion, “To say that we are disappointed is an understatement.”
US Cannabis Council Names Cannabis Veteran Khadijah Tribble as CEO
August 19, 2022
WASHINGTON–Today, the US Cannabis Council (USCC) named Khadijah Tribble, a leading figure in the cannabis reform movement and expert on equity and inclusion, as the organization’s CEO. Tribble succeeds Steven Hawkins, who led USCC since its founding in February 2021.
“We thank Steven Hawkins for his integral role in launching USCC, and we are thrilled to welcome Khadijah Tribble’s to the role of CEO at this critical juncture for the cannabis industry,” said Jessica Billingsley, chair of USCC and CEO of Akerna. “She is deeply respected for her leadership, expertise and wide-ranging experience and is well-positioned to advance our mission of ending prohibition and creating an equitable, values-based industry.”
Tribble serves as Senior Vice President of Corporate Social Responsibility at USCC member company Curaleaf, a role she will continue in during her interim term as CEO. She previously founded Marijuana Matters, a cannabis education and advocacy incubator, and served as CEO of the Marijuana Policy Trust, which helps develop and run DEI programs in the cannabis industry. Tribble, who has advocated for fair and equitable policies on behalf of marginalized communities throughout her career, also serves on USCC’s DEI Task Force. She holds a master’s degree from Harvard University’s John F. Kennedy School of Government.
“The US Cannabis Council unites my deep commitment to cannabis legalization with my passion for addressing the harms of prohibition,” said Tribble. “My priority is advancing meaningful cannabis reforms through Congress this year that will provide the foundation for achieving our ultimate goal of federal descheduling while fostering an equitable and inclusive legal cannabis industry.”
Since launching last year, USCC has established itself as the leading voice for cannabis reform in Washington, DC. The organization has brought cannabis industry CEOs to meet with lawmakers in Congress, partnered with the sponsors of leading cannabis bills to advance reform and launched a campaign to advance passage of the SAFE Banking Act. Earlier this year, USCC launched its DEI Task Force with leaders in law, business and civil rights and partnered with the Congressional Black Caucus Foundation to create an internship program for Black college students and recent graduates at leading cannabis companies and organizations.
1st Hemp USA News is a resource of Inspirational Technologies (2021-2022)Inspirational Technologies (2022) AllRightsReservedYour ONE STOP BLOG FOR INFORMATION, EDUCATION, & INSPIRATION OF ESSENTIAL INNOVATION & RENOVATION of You-THANK YOU FOR YOUR INTEREST*This site receives virtually no compensation for sales of some or all mentioned products. We however place humanitarian value over monetary interests. Our monetary income goes back into research, development, discovery and healing.Inspirational Technologies – is Committed to Your Health Wellness Beauty and EnrichmentReporting on Today’s Internal Botanical and Skin Product Benefits
4 Hemp Club was Inspired by Steven Smith’s vision to
“Have an older generation 4H Club, where an older community of adults could carry on what the younger 4H Club envisioned.
Our 4H Platform Uses HEMP as an Agricultural Focal Point, deserving of research, development and with the
4 Hemp key points being Health Hope and Happiness, thru Hemp“.
Cannabis CBD and Me Inspirational Technologies Inspirational Technologies (2014) @Inspire123tech Background Noise Studios Logos by Steven M Smith
the idea behind the banking legislation is not to make pot legal but to allow businesses that represent the legal cannabis market to use banks, instead of having cash everywhere
It is nothing but a GIANT tax on patients. Think about it:
They want to cap flower at 10%, right? Most flower in FL MMTCs is somewhere between 15% and 25%. A cap as proposed could more than double the price of flower.
And other products would be capped at 60% – when your average vape cart these days is often 85% or more.
Prices are gonna skyrocket. People are gonna go to the black market. Florida’s nearly 500,000 patients are out in the cold.
But it doesn’t have to be that way. We are gonna fight like hell to beat these caps!
